Study of the Influence Of Apitherapy in Acrylamide Experimentally Induced Liver Disease Regarding Blood Count Parameters in Wistar Rats
Abstract
Introduction. The purpose of this experiment was to study the influence of apitherapy in acrylamide-induced liver disease in rats. The experimental study objectives were the evaluation of blood count parameters in conditions of chronic liver damage induced by acrylamide. To reduce the factors that accelerate the progress of liver damage we have administered Apitherapy products. Materials and Methods. Materials: Apitherapy products Apiregya, ApiImunomod, ApiImunostim. The Apitherapy products were purchased from "Stupina LLC. The animals were handled under thiopental induced general anesthesia. Determining the level of investigated parameters, i.e. serum total protein was measured using an automatic analyzer (Aeroset, Abbott) and commercial kits (Abbott, USA). A total of 40 Wistar white rats were used in the study; they were divided evenly into four groups: standard diet control group (group I), apitherapy and royal jelly control group (group II), acrylamide group (group III), acrylamide-apitherapy- royal jelly control group (group IV). The animals were kept under standard light and temperature conditions with access to food and water ad libitum. The toxic liver disease in rats was experimentally induced by gastric gavage administration of acrylamide (in aqueous solution, 50 mg /kg body weight). Results and discussions. The administrationof the apitherapy + RJ to the group that first received the acrylamide (group IV) was effective for maintaining the parameters within limits that were close to the standard food values group (group II) regarding the leukocyte count, erythrocyte number, hemoglobin, hematocrit, VEM, HEM, CHEM, erythrocyte distribution width, thrombocyte count, average thrombocyte volume, width of thrombotic distribution. Conclusions. The study proves that Apitherapy preparations like Apiregya, ApiImunostim, ApiImunomod are efficient in treating liver damage disease and they normalize the liver blood count. Acknowledgments: Financing was done by Human Resources Development Operational Programme through performance by integrating doctorate in European research area project "(PERFORM-ERA) ID 57649.
Authors who publish with this journal agree to the following terms:a) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
